<DOC>
	<DOCNO>NCT01960205</DOCNO>
	<brief_summary>The purpose study examine effect Saxagliptin newly diagnose people pre-diabetes obesity besides lifestyle intervention , evaluate DPP 4 inhibitor reverse pre-diabetes curative effect normal blood sugar , observe influence target obesity relate metabolic abnormality , explore new way intervention population pre-diabetes obesity .</brief_summary>
	<brief_title>Effect Saxagliptin Pre-Diabetes Mellitus Obesity</brief_title>
	<detailed_description>Materials Methods : This perspectiveness , randomize , open study , patient randomly assign standarddose Saxagliptin group , lifestyle intervention group , Metformin group low dose Saxagliptin group 6-month treatment period . Oral glucose tolerance test examine 6 month post-treatment trial .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1.Newly diagnosed insulin resistance glucose intolerance . 2.20 70 year age . 3.BMI≥28kg/m2，or BMI＞25kg/m2 beside waistline≥80cm（female ) ，≥90cm ( male ) . 1 . Under Diabetes Mellitus treatment . 2 . Allergy dipeptidyl peptidase 4 ( DPP4 ) inhibitor . 3 . Active heart failure . 4 . Unwilling unable sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Saxagliptin , prediabetes , glucose intolerance , obesity</keyword>
</DOC>